- Advertisement -
- Results from the FigHTN Phase 2 clinical trial showed baxdrostat, a new medication that inhibits the production of the hormone aldosterone, lowered systolic blood pressure by about 5% when added to the existing medications taken by people with chronic kidney disease and who also have…
